Acinetobacter baumannii is a common cause of serious nosocomial infections. Although
community-acquired infections are observed, the vast majority occur in people with …

Acinetobacter baumannii is a Gram-negative, glucose-non-fermenting, oxidase-negative
coccobacillus, most commonly associated with the hospital settings. The ability to survive in …

Unprecedented levels of antimicrobial resistance in bacterial isolates have prompted great
concerns globally. In 2012 the WHO released a publication outlining the evolving threat of …

Carbapenem is an important therapy for serious hospital‐acquired infections and for the
care of patients affected by multidrug‐resistant organisms, specifically Acinetobacter …

Carbapenem resistance in gram-negative bacteria by production of carbapenemases is one
of the most challenging issues regarding healthcare worldwide. We review the epidemiology …

Acinetobacter baumannii is an opportunistic pathogen that is frequently involved in
outbreaks of infection, occurring mostly in intensive care units. The increasing incidence of …

Carbapenemases are β-lactamase enzymes that hydrolyze a variety of β-lactams including
carbapenem and belong to different Ambler classes (A, B, D). These enzymes can be …

The increasing trend of carbapenem resistance in Acinetobacter baumannii worldwide is a
concern since it limits drastically the range of therapeutic alternatives. Metallo-β-lactamases …

Acinetobacter baumannii is now one of the most frequently encountered nosocomial
pathogens in intensive therapy units, and is renowned for being difficult to treat because of …

Carbapenemases may be defined as β-lactamases that significantly hydrolyze at least
imipenem or/and meropenem. Carbapenemases involved in acquired resistance are of …